Table 3b.
COVID-19 Versus Influenza
| Independent Variable | IVAC,aOR (95% CI) | PVAP,aOR (95% CI) | BSI,aOR (95% CI) | Enterococcus BSI,aOR (95% CI)a | CAUTI,aOR (95% CI)a |
|---|---|---|---|---|---|
| COVID-19 positive | 0.37 (0.05–2.65) | 1.06 (0.07–16.64) | 2.04 (0.41–10.04) | … | … |
| Age, per year | 0.97 (0.91–1.03) | 0.98 (0.91–1.05) | 1.05 (1.01–1.09)b | … | … |
| Male sex | 4.59 (0.61–34.68) | 4.16 (0.25–70.14) | 1.24 (0.41–3.80) | … | … |
| Race or ethnicity | |||||
| Black | … | … | 0.92 (0.16–5.35) | … | … |
| Asian | 0.84 (0.06–10.93) | 4.68 (0.16–139.55) | 0.29 (0.06–1.42) | … | … |
| Hispanic/Latino | 1.09 (0.17–7.13) | 3.65 (0.24–56.35) | 0.47 (0.12–1.85) | … | … |
| Baseline IC | 1.11 (0.18–6.96) | 0.80 (0.04–14.82) | 0.61 (0.18–2.07) | … | … |
| IS meds | 2.98 (0.48–18.69) | 0.24 (0.02–2.58) | 1.20 (0.38–3.75) | … | … |
| ALC<500 | 1.28 (0.19–8.77) | 4.98 (0.32–79.58) | 0.66 (0.19–2.25) | … | … |
| LOS, per day | 0.97 (0.88–1.08) | 0.94 (0.78–1.14) | 1.02 (0.94–1.11) | … | … |
| Central-line days, per day | 0.99 (0.93–1.05) | 0.95 (0.86–1.05) | 0.96 (0.92–1.00) | … | … |
| Ventilator days, per day | 1.18 (1.06–1.32) | 1.05 (0.88–1.24) | 0.85 (0.78–0.94) | … | … |
| No. of blood cultures | 0.87 (0.71–1.07) | 1.14 (0.81–1.63) | 1.55 (1.26–1.91) | … | … |
| Antibiotic days, per day | 1.06 (0.99–1.13) | 1.05 (0.94–1.17) | 1.05 (0.99–1.11) | … | … |
| SOFA | 1.05 (0.84–1.31) | 1.34 (0.96–1.87) | 1.19 (1.01–1.41) | … | … |
Note. CI, confidence interval; IVAC, infection-related ventilator-associated complications; PVAP, probable ventilator-associated pneumonia; BSI, bloodstream infection; CAUTI, catheter-associated urinary tract infection; IC, immunocompromised; IS meds, immunosuppressive medications; ALC<500, absolute lymphocyte count <500 cells/μL at least once during encounter; LOS, length of stay; SOFA, Sequential Organ Failure Assessment score.
a
Unable to evaluate given no events in the influenza group.
b
Covariates significant in the model are in bold.